紫杉醇(Paclitaxel) - 药物靶点：Tubulin_在研适应症：转移性胰腺腺癌，生殖细胞瘤，食管癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

EmPAC、LDE-paclitaxel、NanoPac

+ [72]

靶点

Tubulin

作用机制

微管蛋白抑制剂

治疗领域

肿瘤免疫系统疾病感染+ [12]

在研适应症

转移性胰腺腺癌生殖细胞瘤食管癌+ [154]

非在研适应症

腺泡细胞癌急性淋巴细胞白血病肺腺癌+ [186]

原研机构

National Institutes of Health

在研机构

Clinigen KK

National Cancer InstituteHoffmann-La Roche, Inc.

+ [39]

非在研机构

Inceptua SA

Pfizer Inc.

Celgene Corp.

+ [20]

最高研发阶段批准上市

首次获批日期

美国 (1992-12-29),

艾滋病相关性卡波西肉瘤乳腺癌卵巢癌

最高研发阶段(中国)批准上市

特殊审评孤儿药 (欧盟)、优先审评 (中国)、孤儿药 (美国)

登录后查看时间轴

结构

分子式C47H51NO14

InChIKeyRCINICONZNJXQF-MZXODVADSA-N

CAS号33069-62-4

关联

3,222

项与紫杉醇相关的临床试验

NCT06675136 / Not yet recruiting临床1期IIT

Phase 1 Trial of Nab-Paclitaxel PIPAC (Pressurized Intraperitoneal Aerosolized Chemotherapy) Given in Combination With Second-Line Therapy for Gastric Cancer With Peritoneal Metastases

This phase I trial tests the safety, side effects and best dose of nab-paclitaxel pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in combination with second-line chemotherapy, paclitaxel and ramucirumab, and tests how well they work in treating stomach cancer that has spread from where it first started to the tissue that lines the abdominal wall and organs (peritoneal metastases). Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. PIPAC delivers chemotherapy, such as nab-paclitaxel, that has been turned into a fine mist (aerosolized) at a high pressure directly into the abdominal cavity. Aerosolized chemotherapy delivered directly into the peritoneal space has been shown to deliver higher drug concentrations to the tumor. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving nab-paclitaxel PIPAC in combination with paclitaxel and ramucirumab may be safe, tolerable, and/or effective in treating gastric cancer patients with peritoneal metastases.

开始日期2025-10-17

申办/合作机构

City of Hope National Medical Center

[+1]

NCT06393751 / Not yet recruiting临床1/2期IIT

A Randomized Phase 1/2 Trial Evaluating the Addition of Tolinapant to Weekly Paclitaxel With or Without Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer

This phase I/II trial tests the safety, best dose and effectiveness of adding tolinapant (ASTX660) to paclitaxel with or without bevacizumab in treating patients with ovarian cancer that has come back after a period of improvement (recurrent). Tolinapant may stop the growth of tumor cells by blocking proteins, such as XIAP and cIAP1, that promote the growth of tumor cells and increase resistance to chemotherapy. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to the tumor. This may slow the growth and spread of tumor cells. Adding ASTX660 to paclitaxel with or without bevacizumab may be safe, tolerable and/or effective in treating patients with recurrent ovarian cancer.

开始日期2025-05-02

申办/合作机构

National Cancer Institute

NCT05312372 / Withdrawn临床1/2期IIT

A Phase 1/2, Open -Label, Multicenter Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antineoplastic Activity of S095033 (MAT2A Inhibitor) in Combination With Paclitaxel in Participants With Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

The purpose of this study is to determinate the safety profile, tolerability, pharmacokinetics, and preliminary antineoplastic activity of S095033 in combination with paclitaxel in participants with advanced or metastatic esophageal squamous cell carcinoma (ESCC)

开始日期2025-05-01

申办/合作机构

Institut de Recherches Intern Servier

[+1]

100 项与紫杉醇相关的临床结果

登录后查看更多信息

100 项与紫杉醇相关的转化医学

登录后查看更多信息

100 项与紫杉醇相关的专利（医药）

登录后查看更多信息

39,322

项与紫杉醇相关的文献（医药）

2025-12-01·Journal of Gastrointestinal Cancer

Network Meta-analysis of Randomized Controlled Trials in Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: Comparisons Involving Ramucirumab

Review

作者: Taipale, Kaisa ; Paine, Abby ; Gupta, Palvi ; D'yachkova, Yulia ; Liepa, Astra M ; Earley-Valovic, Veronika ; Goel, Rajat

PURPOSE:

With relatively few direct comparisons among treatment options for previously treated advanced gastric cancer or gastroesophageal junction (GEJ) cancer, network meta-analysis (NMA) may inform evidence-based decision-making. Ramucirumab plus paclitaxel (RAM + PTX) is a preferred regimen in guideline recommendations. NMA of key outcomes may further characterize the relative clinical value of RAM + PTX.

METHODS:

A systematic literature review of randomized controlled trials of adult patients with previously treated advanced gastric/GEJ cancer informed a NMA which compared overall survival, progression-free survival, and discontinuations due to adverse events. Comparisons were reported relative to placebo/best supportive care (BSC) when possible, otherwise relative to RAM + PTX.

RESULTS:

The base-case NMA focused on second-line treatment only, from 19 of 28 studies identified. For overall survival, seven of 16 regimens were favorable relative to placebo/BSC, with RAM + PTX as the most favorable. For progression-free survival, five of 14 regimens were unfavorable relative to RAM + PTX. For discontinuations due to adverse events, two of 13 regimens were similar to placebo/BSC: ramucirumab monotherapy and fluorouracil; relative to RAM-PTX, all regimens were similar except ramucirumab monotherapy which was favorable and irinotecan + cisplatin which was unfavorable.

CONCLUSION:

This NMA of trials of previously treated gastric/GEJ cancer suggests that RAM + PTX has one of the more favorable clinical profiles.

2025-03-01·CELLULAR SIGNALLING

Inhibition of XIST restrains paclitaxel resistance in breast cancer cells by targeting hsa-let-7d-5p/ATG16L1 through regulation of autophagy

Article

作者: Wang, Yueyue ; Zhang, Qiang ; Yang, Yuping ; Pei, Wenhao ; Wang, Fengchao ; Shi, Xiuru ; Geng, Zhijun ; Xia, Chaoqun

Breast cancer is a fatal malignant tumor in women worldwide. The development of paclitaxel resistance remains a challenge. Autophagy is considered to have a significant part in the chemotherapeutic stress mechanism. This study aimed to investigate the function of long non-coding RNA (lncRNA) in breast cancer cell chemoresistance and autophagy. The paclitaxel (PTX)-resistant breast cancer cells were established. The function of X-inactive specific transcript (XIST) was demonstrated using in vitro and in vivo experiments. Transmission electron microscope (TEM) was used to observe autophagy vesicles. Protein and mRNA levels were determined using western blotting and quantitative real time polymerase chain reaction (qRT-PCR). We discovered that autophagic activity was correlated with chemoresistance in PTX-resistant breast cancer cells. In vitro and in vivo studies showed that XIST inhibition reduced cell resistance to paclitaxel, caused autophagy to be suppressed by regulating hsa-let-7d-5p and ATG16L1 expression. Mechanically, threonine protein kinase B (PKB; also known as AKT) - mammalian target of rapamycin (mTOR) pathway was activated when knockdown of XIST, while was reversed by inhibition of hsa-let-7d-5p. Our results verified that XIST played a significant role in developing chemoresistance via mediating autophagy in PTX-resistant breast cancer cells. It may be a potential target for breast cancer treatment strategies.

2025-03-01·COLLOIDS AND SURFACES B-BIOINTERFACES

Enhanced transcytosis and therapeutic efficacy of paclitaxel nanoparticles: Pyridylboronic acid modification and sialic acid targeting

Article

作者: Wang, Xiangtao ; Li, Pengxin ; Zhang, Ziqi ; Li, Manzhen ; Chen, Miao ; Yu, Han

Efficient drug delivery and deeper penetration into tumors have become a primary focus of anti-tumor nanomedicine. In this study, pyridylboronic acid (BPA), as a targeting ligand for sialic acid, which is highly expressed on the surface of tumor cells, was conjugated with DSPE-PEG2k-NH₂ to synthesize DSPE-PEG2k-BPA and used to encapsulate PTX. The resultant PTX@DSPE-PEG2k-BPA nanoparticles (DPB NPs) showed a mean particle size of 189.0 ± 3.5 nm, with a high drug loading content of 48.75 % and a rod-like morphology. In contrast to PTX@DSPE-mPEG2k nanoparticles (DP NPs), DPB NPs displayed enhanced cellular uptake and targetability to 4T1 tumor cells. Interestingly, BPA modification could also enhance transcytosis through the endoplasmic reticulum-Golgi pathway, thus improving penetration and accumulation of nanoparticles in tumors. An in vivo study on 4T1 tumor-bearing mice demonstrated that DPB NPs achieved a faster and more accumulation in tumors than DP NPs after intravenous administration, led to significantly improved therapeutic efficacy with a higher tumor inhibition rate (74.27 % vs 50.58 %, p < 0.01). In conclusion, the modification of BPA presents a strategy for the development of drug delivery systems that exhibit dual functionalities: active targeting and transcytosis.

2,620

项与紫杉醇相关的新闻（医药）

2025-01-23

·ir.alxoncology.com

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 - 25, 2025. ASPEN-06 is a randomized, multi-center, international trial (NCT05002127) evaluating evorpacept, ALX Oncology’s investigational CD47-blocking therapeutic that uniquely combines a high-affinity CD47-binding domain with an inactivated proprietary Fc domain, in combination with trastuzumab, CYRAMZA® (ramucirumab) and paclitaxel (collectively, TRP) against TRP alone for the treatment of patients with HER2-positive gastric/gastroesophageal junction cancer, where all patients had received an anti-HER2 agent in prior lines of therapy. The updated results from the ASPEN-06 study will be detailed in the following oral presentation: Title: Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC)Abstract Number: 332Presenter: Kohei Shitara, MD, Director of the Department of Gastrointestinal Oncology, at National Cancer Center Hospital East, Kashiwa in JapanPresentation Date and Time: Thursday, January 23, 2025, from 9:15 a.m. – 10:00 a.m. PSTSession Information: Rapid Oral Abstract Session A: Cancers of the Esophagus and StomachLocation: Level 2 Ballroom Copies of the presentations will be available on the Publications section of ALX Oncology’s website following presentation at the meeting. About ALX OncologyALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology. Company Contact: Caitlyn Doherty, Manager, Corporate Communications, ALX Oncology cdoherty@alxoncology.com (650) 466-7125 Media Contact: Audra Friis, Sam Brown, Inc. audrafriis@sambrown.com (917) 519-9577

ASCO会议临床2期免疫疗法临床结果

2024-12-18

·药明康德

“史无前例！”100%患者持久无癌超2年，GSK单抗一线疗法获FDA突破性疗法认定

▎药明康德内容团队编辑 GSK日前宣布，美国FDA已授予其PD-1抑制剂Jemperli（dostarlimab）用于治疗局部晚期错配修复缺陷（dMMR）/高微卫星不稳定性（MSI-H）直肠癌的突破性疗法认定（BTD）。根据新闻稿，这是dostarlimab在局部晚期dMMR/MSI-H直肠癌适应症上获得的第二项监管认定，该疗法在2023年1月曾获FDA授予快速通道资格。直肠癌是一种始发于直肠的大肠癌，常被归类为结直肠癌的一部分。结直肠癌是全球第三大最常见的癌症。在美国，每年约有4.6万例新确诊的直肠癌病例，其中约5-10%属于dMMR/MSI-H类型。这类肿瘤因DNA修复功能异常而导致复制错误。研究表明，dMMR是一种能预测PD-1免疫检查点抑制疗法疗效的重要生物标志物。具有此标志物的肿瘤通常见于子宫内膜癌、结直肠癌及其他胃肠道癌症中，也可能出现于其他类型的实体瘤。目前，局部晚期dMMR/MSI-H直肠癌的标准治疗方案包括初期化疗联合放疗，随后进行手术切除肿瘤及部分肠道或周围组织。尽管这种疗法在多数患者中可取得初步疗效，但近三分之一的患者最终因癌症转移而死亡。此外，标准治疗中的手术及放化疗可能对患者生活质量产生长期负面影响，例如肠道、泌尿及性功能障碍，以及继发性癌症和不孕不育问题。这次突破性疗法认定的授予主要基于一项由GSK支持并与纪念斯隆凯特琳癌症中心合作开展的2期临床试验的初步数据。试验显示，接受并完成dostarlimab作为一线疗法的42名局部晚期dMMR直肠癌患者，达成前所未有的100%临床完全缓解（cCR）率，即通过磁共振成像（MRI）、内镜检查、正电子扫描（PET）和直肠指检（DRE）皆未检测到肿瘤。在首批24名患者中，中位随访时间为26.3个月（95% CI：12.4-50.5）时，观察到持续性的cCR。 Dostarlimab的安全性和耐受性与其已知的安全特征总体一致。在试验中，未报告任何3级或更高级别的不良事件。试验仍持续进行以进一步评估患者的疗效。 GSK全球肿瘤研发高级副总裁Hesham Abdullah博士表示：“这一突破性疗法认定主要基于dostarlimab所展现前所未有的100%临床完全缓解率。这标志着为局部晚期dMMR/MSI-H直肠癌患者改变治疗模式迈出了重要一步。这些患者面临长期生活质量受损的风险，而我们的注册性AZUR-1临床2期试验正在继续探索dostarlimab在这一患者群体中的应用前景。” Dostarlimab是一种能够与PD-1受体结合，并阻断其与配体PD-L1和PD-L2交互作用的抗体。Dostarlimab在2021年4月获美国FDA批准，作为在先前接受过含铂疗法后的dMMR晚期或复发性子宫内膜癌的单药治疗。该疗法并在2023年7月获批与卡铂和紫杉醇联合用药，并接续dostarlimab作为单药以治疗由美国FDA批准的检测方法确定为dMMR或MSI-H的原发性晚期或复发性子宫内膜癌成人患者。此外，dostarlimab在2021年8月获FDA加速批准用于治疗携带dMMR的复发或晚期实体瘤患者，这些患者的dMMR特征由FDA批准的检测确认，在接受前期治疗后疾病继续进展，并且没有其它满意的替代治疗选择。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料： [1] Jemperli (dostarlimab) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer. Retrieved December 18, 2024 from https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-receives-us-fda-breakthrough-therapy-designation-for-locally-advanced-dmmrmsi-h-rectal-cancer/ 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

突破性疗法临床2期快速通道

2024-12-18

·医学新视点

“癌症之王”靶病灶100%缩小！创新疗法为患者带来新选择

▎药明康德内容团队编辑 Actuate Therapeutics日前公布其在研GSK-3β小分子抑制剂elraglusib联合吉西他滨/白蛋白紫杉醇（GnP），用于转移性胰腺导管腺癌（mPDAC）一线治疗2期试验Actuate-1801 Part 3B的积极结果。 Actuate-1801 Part 3B研究是一项随机对照的2期临床试验，旨在评估elraglusib联合GnP与GnP单独相比，作为mPDAC一线治疗中的疗效和安全性。该研究共纳入286例未接受过系统性治疗的mPDAC患者，按2：1的比例随机分配至elraglusib联合治疗组（elraglusib + GnP）或对照组（GnP单独治疗）。中期数据分析显示，试验达成主要终点。Elraglusib联合治疗组患者的1年生存率为43.6%，显著高于活性对照组的22.5%（p=0.002）。其中elraglusib联合治疗组患者的18个月与24个月生存率分别为20.9%和16.7%，而活性对照组则皆为0%。Elraglusib联合治疗组患者的死亡风险降低了37%，中位总生存期（mOS）显著延长至9.3个月，而活性对照组患者的mOS则为7.2个月（HR=0.63，p=0.016）。 ▲Actuate Therapeutics管线图（图片来源：Actuate Therapeutics公司官网）截至2024年11月15日，elraglusib联合治疗组与活性对照组患者的客观缓解率（ORR）分别为27.7%与20.5%；疾病控制率（DCR）分别为42.6%与33.3%；无进展生存期（PFS）分别是5.6个月与4.9个月。值得一提的是，elraglusib联合治疗组中有2例原本不可手术的患者，经过治疗后靶病灶明显缩小，成功接受了手术切除，其中1例在手术后达到了100%肿瘤负荷清除。此外，该组还观察到1例完全缓解（CR）和1例部分缓解（PR），两者均实现了靶病灶100%缩小，而对照组未出现类似结果。安全性方面，试验达到了主要的安全性终点。Elraglusib联合治疗组的不良事件（TEAEs）和严重不良事件（SAEs）与活性对照组相似，显示出良好的风险-获益特征。 Elraglusib（9-ING-41）是一种选择性的强效GSK-3β抑制剂，已在临床试验中显示出积极的抗癌活性。目前，elraglusib正在开发用于治疗mPDAC。在临床前模型中，elraglusib表现出免疫调节作用，并在临床样本中显示出对血清细胞因子谱的调节能力。相关阅读减少化疗，疗效相当，还更安全！《柳叶刀》子刊：转移性胰腺癌新治疗策略《柳叶刀》子刊：胰腺癌获突破性进展！溶瘤病毒疗法安全可行医科院肿瘤医院：每16人就有1人会死于消化系统癌症参考资料： [1] Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer. Retrieved December 17, 2024 from https://www.globenewswire.com/news-release/2024/12/17/2998209/0/en/Actuate-Therapeutics-Announces-Positive-Interim-Phase-2-Data-of-Elraglusib-in-First-Line-Treatment-of-Metastatic-Pancreatic-Cancer.html [2] 2024-ASCO-Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study. Retrieved December 17, 2024 from https://actuatetherapeutics.com/wp-content/uploads/2024/09/Weiskittel-Publication-Pancreatic-cancer-ASCO-2024.pdf 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，传递医学新知

临床结果临床2期

100 项与紫杉醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00491	紫杉醇	L01CD01	DB01229

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
转移性胰腺腺癌	欧盟	Accord Healthcare SLU	2024-01-05
转移性胰腺腺癌	冰岛	Accord Healthcare SLU	2024-01-05
转移性胰腺腺癌	列支敦士登	Accord Healthcare SLU	2024-01-05
转移性胰腺腺癌	挪威	Accord Healthcare SLU	2024-01-05
铂类耐药性原发性腹膜癌	欧盟	Inceptua SA	2018-11-20
铂类耐药性原发性腹膜癌	冰岛	Inceptua SA	2018-11-20
铂类耐药性原发性腹膜癌	列支敦士登	Inceptua SA	2018-11-20
铂类耐药性原发性腹膜癌	挪威	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	欧盟	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	冰岛	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	列支敦士登	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	挪威	Inceptua SA	2018-11-20
铂敏感性输卵管癌	欧盟	Inceptua SA	2018-11-20
铂敏感性输卵管癌	冰岛	Inceptua SA	2018-11-20
铂敏感性输卵管癌	列支敦士登	Inceptua SA	2018-11-20
铂敏感性输卵管癌	挪威	Inceptua SA	2018-11-20
生殖细胞瘤	日本	Clinigen KK	2013-02-21
生殖细胞瘤	日本	Bristol Myers Squibb Co.	2013-02-21
食管癌	日本	Bristol Myers Squibb Co.	2012-03-21
食管癌	日本	Clinigen KK	2012-03-21

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰腺癌	申请上市	欧盟	Accord Healthcare SLU	2023-11-09
高级别胶质瘤	临床3期	中国	浙江大学	2024-04-01
HEGF2阴性乳腺癌	临床3期	中国	上海谊众药业股份有限公司	2023-09-25
三阴性乳腺癌	临床3期	美国	Hoffmann-La Roche, Inc.	2019-11-25
三阴性乳腺癌	临床3期	日本	Hoffmann-La Roche, Inc.	2019-11-25
三阴性乳腺癌	临床3期	阿根廷	Hoffmann-La Roche, Inc.	2019-11-25
三阴性乳腺癌	临床3期	澳大利亚	Hoffmann-La Roche, Inc.	2019-11-25
三阴性乳腺癌	临床3期	奥地利	Hoffmann-La Roche, Inc.	2019-11-25
三阴性乳腺癌	临床3期	比利时	Hoffmann-La Roche, Inc.	2019-11-25
三阴性乳腺癌	临床3期	巴西	Hoffmann-La Roche, Inc.	2019-11-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02312245 (CTgov)	临床2期	铂耐药性输卵管癌 \| 复发性卵巢癌 \| 复发性原发性腹膜癌	13	Paclitaxel+Bevacizumab (Arm A (Avatar-directed Paclitaxel))	膚鹽願窪鏇積膚壓繭夢(蓋網簾觸膚醖餘窪獵願) = 製遞願繭醖蓋廠鏇鹹蓋網糧餘糧蓋夢艱壓鏇製 (淵淵蓋齋鑰鬱鑰窪窪襯, 窪衊願網醖憲製選範窪 ~ 膚製廠築觸齋網鏇繭遞) 更多	-	2024-12-05
				Gemcitabine Hydrochloride (Arm B (Avatar-directed Gemcitabine Hydrochloride))	膚鹽願窪鏇積膚壓繭夢(蓋網簾觸膚醖餘窪獵願) = 鬱壓廠醖顧襯積製鬱鹽網糧餘糧蓋夢艱壓鏇製 (淵淵蓋齋鑰鬱鑰窪窪襯, 鑰構齋廠衊築網夢簾膚 ~ 鑰繭鑰製夢鹹鑰膚艱選) 更多
NCT03393884 (OVATION-2, SITC2024) 人工标引	临床1/2期	卵巢上皮癌一线	117	IMNN-001 + NACT	膚積鹽憲鑰願鹽憲築範(獵淵鏇鏇餘鑰網鹽網廠) = 夢醖積襯窪選襯網網願願範範獵願糧簾蓋醖觸 (選淵壓壓壓鏇積糧顧選 ) 更多	积极	2024-11-08
				NACT	膚積鹽憲鑰願鹽憲築範(獵淵鏇鏇餘鑰網鹽網廠) = 築醖網艱鏇壓醖糧糧淵願範範獵願糧簾蓋醖觸 (選淵壓壓壓鏇積糧顧選 ) 更多
NCT00980954 (CTgov)	临床3期	宫颈癌	236	intensity-modulated radiation therapy+cisplatin (Arm I: Cisplatin/Radiation Therapy)	鹽窪齋廠壓艱選衊鏇蓋(繭顧廠鹹製鑰遞願淵製) = 鑰鹽製積醖艱網範齋網齋鑰憲糧衊糧窪衊淵憲 (鏇範糧糧襯獵鏇夢鏇選, 窪餘醖膚醖製築餘積糧 ~ 蓋積築繭選糧鏇鹽製廠) 更多	-	2024-11-06
				intensity-modulated radiation therapy+carboplatin+paclitaxel+cisplatin (Arm II: Cisplatin/Radiation Therapy + Carboplatin/Paclitaxel)	鹽窪齋廠壓艱選衊鏇蓋(繭顧廠鹹製鑰遞願淵製) = 鏇鏇艱餘築蓋範築繭構齋鑰憲糧衊糧窪衊淵憲 (鏇範糧糧襯獵鏇夢鏇選, 艱鏇膚壓蓋艱糧選網淵 ~ 觸鹽觸遞廠廠壓壓顧憲) 更多
NCT01042522 (NRG oncology/gynecologic oncology group study14, Pubmed \| Gynecol Oncol)	临床2期	卵巢癌	63	Paclitaxel and Carboplatin (PC)	餘鑰觸憲糧壓製獵繭淵(選鹽鏇醖繭齋窪獵願獵) = 觸簾繭廠觸鹽憲願糧顧夢觸範鬱願憲夢願衊膚 (簾積夢構鏇繭廠糧窪顧, 11.2 ~ 41.0)	不佳	2024-11-01
				Bleomycin, Etoposide, and Cisplatin (BEP)	餘鑰觸憲糧壓製獵繭淵(選鹽鏇醖繭齋窪獵願獵) = 繭顧餘選壓顧蓋窪製齋夢觸範鬱願憲夢願衊膚 (簾積夢構鏇繭廠糧窪顧, 10.4 ~ 52.7)
NCT02713386 (NRG-GY007 \| NRG Oncology Group Study, CTgov)	临床1/2期	原发性腹膜癌 \| 原发性腹膜高级别浆液性腺癌 \| 输卵管透明细胞腺癌 ... 更多	147	Therapeutic Conventional Surgery+Carboplatin+Paclitaxel (Arm I (Paclitaxel and Carboplatin))	鹹選廠繭淵鑰積製衊範(廠選鬱淵膚壓糧鬱積繭) = 獵簾顧膚網範構願網鏇網廠願齋築壓積齋製糧 (繭鬱鏇艱觸膚窪遞鬱願, 襯顧顧鑰鑰艱齋衊簾網 ~ 網鹹餘顧遞遞鏇範襯觸) 更多	-	2024-10-24
				Therapeutic Conventional Surgery+Carboplatin+Paclitaxel+Ruxolitinib Phosphate (Arm II (Ruxolitinib, Paclitaxel, and Carboplatin))	鹹選廠繭淵鑰積製衊範(廠選鬱淵膚壓糧鬱積繭) = 範鬱觸淵範選衊膚廠選網廠願齋築壓積齋製糧 (繭鬱鏇艱觸膚窪遞鬱願, 鹹廠衊衊窪觸選襯遞願 ~ 窪艱簾壓廠醖鑰夢壓餘) 更多
NCT04325698 (CTgov)	临床3期	非鳞状非小细胞肺癌	8	PF-06439535 (PF-06439535 (CN))	艱壓鬱艱夢夢願餘網構(觸鹽膚積艱鹹築壓遞築) = 襯鏇積蓋糧鹹糧選選遞夢繭構憲獵繭艱構夢遞 (餘遞鬱壓鑰獵鹹鹽夢襯, 願餘憲獵齋襯簾窪遞襯 ~ 遞膚選鹹夢觸衊鹽網鏇) 更多	-	2024-10-01
				Bevacizumab (Bevacizumab (EU))	艱壓鬱艱夢夢願餘網構(觸鹽膚積艱鹹築壓遞築) = 壓鏇壓蓋簾淵遞淵糧觸夢繭構憲獵繭艱構夢遞 (餘遞鬱壓鑰獵鹹鹽夢襯, 襯廠醖淵選醖網觸鹽製 ~ 顧膚繭憲襯鏇網繭壓憲) 更多
NCT05065021 (Re-VOLVE, ESMO2024) 人工标引	临床2期	卵巢癌	20	Niraparibniraparibbevacizumabpaclitaxeldostarlimab	壓選顧醖築鹹襯膚鬱願(鏇窪蓋鹽製築範膚衊醖) = 範觸衊窪網餘觸齋願鏇簾窪積鬱製糧鏇鬱衊簾 (衊鹹醖顧鑰蓋蓋築顧築 ) 更多	积极	2024-09-14
NCT02492867 (CTgov)	N/A	局部晚期非小细胞肺癌	49	V/Q SPECT+Carboplatin+Paclitaxel+Durvalumab	艱廠獵鏇憲願淵獵願糧(餘遞獵糧蓋襯鬱範鬱簾) = 衊窪餘糧遞衊衊鏇鏇鹽鏇蓋襯網選艱廠齋範淵 (範鏇構憲襯選廠鏇獵糧, 鬱壓範願齋衊構艱簾膚 ~ 觸鬱簾糧獵築築築積構) 更多	-	2024-09-03
NCT03141359 (LCI-LUN-NSC-SBRT-001, CTgov)	临床2期	非小细胞肺癌 II期 \| 局部晚期恶性肿瘤 \| 局部晚期非小细胞肺癌	61	Platinum+Etoposide+Carboplatin+Paclitaxel+durvalumab	齋衊顧構蓋觸網願餘觸(製膚齋願鬱餘構衊網範) = 鑰憲鏇糧淵壓醖製襯鹽築獵鹹糧遞選憲廠淵鑰 (夢衊鏇窪窪膚網選壓繭, 範齋築憲範願夢廠鹹襯 ~ 夢夢簾蓋鹽構構窪繭糧) 更多	-	2024-08-29
NCT03206177 (CTgov)	临床1期	卵巢癌肉瘤	26	Galunisertib+Carboplatin+Paclitaxel	簾製齋鬱獵獵鏇壓艱襯(壓鬱觸艱築顧壓壓繭鬱) = 獵簾積網醖夢膚蓋齋獵遞願窪獵範鏇顧餘網鬱 (艱壓鬱積齋鬱積壓蓋醖, 廠鬱蓋觸選鏇範衊夢醖 ~ 構淵鹹醖艱醖壓鏇顧窪) 更多	-	2024-08-07